To receive the Femtech World newsletter, sign up here.
Fertility
BMI cut-offs for IVF inconsistent throughout UK clinics, study finds
Researchers found inconsistencies when comparing UK clinics, Integrated Care Boards and international guidelines

BMI cut-offs for IVF care are inconsistent and may have discriminating implications, a new study of 32 UK fertility clinics has shown.
The research, conducted by the fertility clinic Ovom, focused on BMI as a treatment eligibility criterion and the thresholds across the UK.
It found that the imposed BMI cut-offs for IVF care were inconsistent between clinics, source of funding, other countries and different guidelines, raising concerns about violation of ethical principles of patient autonomy, beneficence/non-maleficence and justice, especially given that most BMI cut-offs only applied to women.
The study, entitled Discrepancies in upper body mass index (BMI) IVF treatment eligibility limits across UK clinics and international borders with implications for access to fertility services for women in particular, was led by MyFertility, Orchid Fertility and Ovom Care and included responses from 32 clinics throughout the UK.
The clinics were asked if they had a BMI limit to treat IVF patients and if so, what the limit was. Integrated Care Boards thresholds were collected and national and international standards were consulted for BMI cut-offs.
Researchers found inconsistencies when comparing UK clinics, Integrated Care Boards and international guidelines.
For UK clinics, the BMI cut-off varied from BMI 29.9 to 40, with most clinics having a threshold BMI<35, the research showed. Private clinics had a higher BMI cut-off compared to NHS clinics.
In all clinics that offered both NHS and private care, the cut-off for private patients was higher than that for NHS, despite the patients being treated in the same clinic.
Of the 42 British Integrated Care Boards, 35 published policies with treatment eligibility criteria, all stating BMI range between 19 and 30 at the time of referral and commencement of treatment, yet 44 per cent of the UK female population of reproductive age experience BMI>30, posing a real challenge for almost half of the female population unable to access fertility care because of their BMI.
This inconsistency was also seen internationally, with some countries like Australia and New Zealand having a BMI<35 threshold, while countries like the US and Israel having no BMI thresholds. Women with a BMI of over 50 had a 21 per cent chance of live birth per cycle.
“This is an important study as it sheds light on the labyrinth of obstacles and hurdles that are placed in front of people with a high BMI to have fertility care,” explained Dr Lynae Brayboy, co-founder and chief medical officer at Ovom.
“The imposition of arbitrary cut-offs not based on data for IVF is discriminatory and marginalises women, people with ovaries and couples unnecessarily.”
Fertility
AI could transform ovarian care through personalisation, study finds

AI could transform ovarian care by personalising cancer and fertility treatment, but more clinical validation is needed before routine use.
A systematic review and meta-analysis found AI models showed high diagnostic accuracy for ovarian cancer when combining data such as ultrasound scans and blood test results.
Across 81 studies, AI models correctly identified ovarian cancer in around nine out of 10 cases, with pooled rates of 89 to 94 per cent.
They were also highly accurate at ruling out ovarian cancer when it was not present, with specificity of 85 to 91 per cent.
The analysis also found that explainable AI tools could predict complete surgical cytoreduction in advanced ovarian cancer.
Complete surgical cytoreduction means removing all visible cancer during surgery, which can be an important goal in treatment planning.
The tools achieved a pooled AUC of 0.87. AUC is a measure of how well a model distinguishes between different outcomes, with higher scores showing stronger performance.
In reproductive medicine, AI algorithms helped physicians optimise ovarian stimulation protocols and predict follicular growth during IVF.
Ovarian stimulation is the use of hormones to encourage the ovaries to produce eggs, while follicles are the small sacs in the ovaries where eggs develop.
The review found AI could reliably model ovarian response in IVF with a pooled AUC of 0.81.
However, researchers said challenges remain in translating promising research findings into routine clinical practice.
They identified substantial variation across studies, driven by retrospective study designs, variable AI systems and a lack of standardised validation.
Only 22 per cent of analysed studies reported prospective, multicentre external validation, where models are tested forward in time across multiple healthcare settings.
The authors called for rigorous validation to help close the gap between research and routine clinical practice, alongside standardised methodological and reporting frameworks, smooth integration with clinical workflow and robust governance to support responsible and ethical AI use.
They concluded: “Artificial intelligence is a transformative force in the management of ovarian conditions.
“In gynaecologic oncology, AI enhances every phase of care, from early detection and accurate diagnosis to prognostic stratification and surgical planning.”
In reproductive medicine, AI personalises ovarian stimulation and refines the diagnosis of heterogenous endocrine disorders such as PCOS.
PCOS, or polycystic ovary syndrome, is a hormonal condition that can affect periods, skin, weight and fertility.
Fertility
Housing, work and fertility stop Britons having the families they want – research
Fertility
Femtech World reveals fertility innovation award shortlist

Femtech World is thrilled to reveal the shortlist for the Fertility Innovation Award.
The award, sponsored by FinDBest IVF, celebrates a pioneering product, service or initiative that is transforming fertility care and support.
FinDBest IVF is a global B2B digital platform created to simplify and accelerate how IVF and ART manufacturers connect with trusted, pre-vetted distributors around the world.
This year’s nominees represent a remarkable breadth of approaches to fertility care: from clinic-floor breakthroughs to at-home hormone intelligence to truly borderless access.
Three companies made the cut, with each tackling a real, persistent barrier in reproductive health.
Congratulations to the shortlist and many thanks to everyone who entered.
Fertility Innovation Award Shortlist

HRC Fertility’s Needle-Free IVF is a pioneering advancement designed to transform one of the most challenging aspects of fertility treatment: daily hormone injections.
Developed by board-certified reproductive endocrinologist Dr Rachel Mandelbaum, this innovative approach reimagines how stimulation medications are delivered during IVF and egg freezing, dramatically improving the patient experience while maintaining the same trusted clinical outcomes.
Inspired by feedback from patients who struggled with the injection process, Dr Mandelbaum adapted an innovative drug-delivery system commonly used in other areas of medicine and applied it to reproductive care

Mira is a hormonal health technology company that provides lab-grade hormone testing and AI-driven insights to help women and couples understand their fertility.
The platform has already supported more than 200,000 couples on their fertility journeys worldwide, helping over 60,000+ users achieve pregnancy.
For some users, pregnancy rates have reached up to 89 per cent within six months, demonstrating how accurate hormone data can significantly improve fertility outcomes.

Founded in 2021 by Marija Skujina, a Certified Fertility Nurse Specialist accredited by the European Society of Human Reproduction and Embryology, with nearly 15 years of clinical experience at one of the world’s top IVF clinics, and having navigated her own fertility journey as a patient, Marija built the clinic she had always wished existed.
Plan Your Baby began with a bold, but simple mission – make best quality fertility and pregnancy available anywhere.
Plan Your Baby has created a new generation fertility and pregnancy clinic with patients accessing expert consultations remotely, while blood tests and ultrasound scans are available at over 450 locations across the UK, eliminating the exhausting travel burden that often forces people to take days off work, relocate appointments, or abandon treatment altogether
What happens now
The shortlist will be judged by a representative from category sponsor FindBestIVF, with the winner announced at a virtual event on June 19.
Winners will receive a trophy and be interviewed by a Femtech World journalist.
News4 weeks agoWomen’s digital health market set to reach US$5.28 billion in 2026 – report
Insight4 weeks agoWhy the UK’s fertility rate keeps falling – and what it means if you’re trying now
Events4 weeks agoWomen’s HealthX unveils Northwell Health, Corewell Health, Biogen & more to headline Chronic Disease stage
Opinion3 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
Fertility4 weeks agoToxins and climate harms having ‘alarming’ effect on fertility, research warns
News3 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Events2 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Fertility4 weeks agoResearcher explores weight loss jab impact on PCOS













2 Comments